PARTI Overview We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (PD-1) inhibitor, LOQTORZI (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma (NPC) and advance the development of new indications for LOQTORZI in combination with both our pipeline candida...
Q2 FY2026 — expected 2026-09-05
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-09 | 2025-12-31 | 0001104659-26-025308 | EDGAR | 91K words |
| 2025-03-17 | 2024-12-31 | 0001558370-25-003126 | EDGAR | — |
| 2024-03-15 | 2023-12-31 | 0001558370-24-003436 | EDGAR | — |
| 2023-03-06 | 2022-12-31 | 0001558370-23-002917 | EDGAR | — |
| 2022-02-23 | 2021-12-31 | 0001558370-22-001764 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001558370-21-001829 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001564590-20-007416 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001564590-19-005470 | EDGAR | — |
| 2018-03-08 | 2017-12-31 | 0001564590-18-004947 | EDGAR | — |
| 2017-03-14 | 2016-12-31 | 0001564590-17-004176 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001104659-25-107852 | EDGAR | 60K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010803 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001558370-25-007418 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001558370-24-014648 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011629 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001558370-24-007641 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0001558370-23-017779 | EDGAR | — |
| 2023-08-02 | 2023-06-30 | 0001558370-23-012915 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001558370-23-008529 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001558370-22-016850 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001558370-22-012251 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001558370-22-007420 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-09 | 0001104659-26-025293 | EDGAR | 5K words |
| 2026-02-17 | 0001104659-26-016378 | EDGAR | — |
| 2026-02-04 | 0001104659-26-010065 | EDGAR | — |
| 2026-01-23 | 0001104659-26-006307 | EDGAR | — |
| 2026-01-13 | 0001104659-26-003117 | EDGAR | — |
| 2025-11-13 | 0001104659-25-111484 | EDGAR | — |
| 2025-11-06 | 0001104659-25-107780 | EDGAR | — |
| 2025-09-08 | 0001558370-25-011911 | EDGAR | — |
| 2025-08-07 | 0001558370-25-010802 | EDGAR | — |
| 2025-07-03 | 0001558370-25-009085 | EDGAR | — |
280 total filings indexed. 248 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001512762 |
| Ticker | CHRS |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.coherus.com |
| Listed | 2014-11-06 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report